Syndax posts R&D Day presentation on revumenib and axatilimab pipeline expansion
SNDX•R&D Day presentation highlights growth plans
Syndax outlined growth plans built around Revuforj (revumenib) in acute leukemia, Niktimvo (axatilimab) in chronic GVHD, and pipeline expansion.
Revuforj and Niktimvo were annualizing at about $200 million each as of 1Q26, supporting a push toward profitability.
Revuforj was positioned as the first menin inhibitor targeting frontline AML; regulatory submission is targeted for 4Q26.
Pipeline build-out includes EGFR and myelofibrosis programs
The pipeline build-out highlighted SNDX-4321, a mutant-selective allosteric EGFR inhibitor for EGFR-mutant NSCLC, targeting an IND submission in 2027.
The next-generation menin program is led by SNDX-62122 for myelofibrosis, targeting an IND submission in 2027.
